{"id":2443,"date":"2017-12-04T11:40:23","date_gmt":"2017-12-04T06:10:23","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2443"},"modified":"2025-05-12T14:41:48","modified_gmt":"2025-05-12T09:11:48","slug":"toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","title":{"rendered":"Toll-Like Receptor Modulators: Emerging therapy for many indications"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Toll-like receptors<\/strong> are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in <strong>Drosophila melanogaster<\/strong> in the late 20<sup>th<\/sup> century which later led to the identification of mammalian homologs. Human TLR family consists of 10 different receptors named <strong>TLR1-TLR10<\/strong>. TLRs are necessary for the recognition of microbes, and the subsequent development of host immunity against the pathogen.<\/p>\n<p style=\"text-align: justify;\">However, TLRs have also been implicated in the development of various immune disorders. Overstimulation of innate immune cells and inflammatory factors mediated by TLR has been established to be the main reason for the development of conditions like chronic enterocolitis, atherosclerosis, rheumatoid arthritis and even allograft rejections. Therefore, the development of specific TLR antagonist is an active area of clinical and non-clinical research. Some of the companies in this class include <strong>Novimmune<\/strong> and <strong>Idera Pharmaceuticals<\/strong>.<\/p>\n<p style=\"text-align: justify;\">On the other hand, activation of TLR mediated signaling pathways has proven to be highly useful in the development of specific immune response against various cancer cells. Consequently, TLR agonists are also being actively researched and developed by many companies like <strong>Immune Design<\/strong> and <strong>GlaxoSmithKline<\/strong>. Further, the TLR pathway agonists are also being developed as specific cancer vaccines and\/or adjuvants for such vaccines.<\/p>\n<p style=\"text-align: justify;\">Overall, targeting TLR pathway and its modulation has immense potential for the treatment of many indications including but not limited to, immune disorders and cancers. Key players in the development of TLR pathway modulators include <strong>Hemispherex<\/strong> that is striving hard to obtain the FDA approval for its highly publicized candidate, <strong>Ampligen<\/strong>. <strong>Mologen<\/strong> and<strong> InDex Therapeutics<\/strong> are also emerging as potential market players and have a drug candidate each in <strong>Phase III<\/strong> stage of clinical development.<\/p>\n<p style=\"text-align: justify;\">The highly robust and rapidly growing pipeline of toll-like receptor modulators is an indication of the immense therapeutic as well as the market potential of targeting this mechanism of action. It is expected that these drugs will impact the therapeutic landscape post-launch.<\/p>\n<p><em>Insight By:<br \/>\n<\/em><em>Iswarya Srinivasan<br \/>\n<\/em><em>Trainee<\/em><\/p>\n<p><em>&nbsp;<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in Drosophila melanogaster in the late 20th century which later led to the identification of mammalian homologs. Human TLR family consists of 10 different receptors named TLR1-TLR10. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2444,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1167,169,1155,204,1207,1216,985,1212,1210,1211,1215,1203,381,1214,1209,1156,1204,1196,1205,1208,17603,1206],"industry":[17225],"therapeutic_areas":[17278],"class_list":["post-2443","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-business-consultants","tag-clinical-trials","tag-consultancy","tag-delveinsight","tag-drosophila-melanogaster","tag-emerging-therapeutics","tag-glaxosmithkline","tag-hemispherex","tag-idera-pharmaceuticals","tag-immune-design","tag-index-therapeutics","tag-industry-reports","tag-market-research","tag-mologen","tag-novimmune","tag-pharma-consultant","tag-pharma-reports","tag-pharma-research","tag-pharmaceutical-reports","tag-tlr1-tlr10","tag-toll-like-receptor-modulatorsampligen","tag-toll-like-receptors","industry-pharmaceutical","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Toll-Like Receptor Modulators :A brief review | Delveinsight<\/title>\n<meta name=\"description\" content=\"Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Toll-Like Receptor Modulators :A brief review | Delveinsight\" \/>\n<meta property=\"og:description\" content=\"Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-04T06:10:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:11:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"852\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Toll-Like Receptor Modulators :A brief review | Delveinsight","description":"Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","og_locale":"en_US","og_type":"article","og_title":"Toll-Like Receptor Modulators :A brief review | Delveinsight","og_description":"Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals.","og_url":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-12-04T06:10:23+00:00","article_modified_time":"2025-05-12T09:11:48+00:00","og_image":[{"width":852,"height":480,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","url":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications","name":"Toll-Like Receptor Modulators :A brief review | Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2.jpg","datePublished":"2017-12-04T06:10:23+00:00","dateModified":"2025-05-12T09:11:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/toll-like-receptor-tlr-modulators-emerging-therapy-many-indications#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2.jpg","width":852,"height":480},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09024203\/2-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">business consultants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drosophila melanogaster<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Emerging therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemispherex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Idera Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immune Design<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">InDex Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">industry reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Mologen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharmaceutical reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TLR1-TLR10<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Toll Like Receptor ModulatorsAmpligen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Toll-like receptors<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business consultants<\/span>","<span class=\"advgb-post-tax-term\">Clinical trials<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Drosophila melanogaster<\/span>","<span class=\"advgb-post-tax-term\">Emerging therapeutics<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Hemispherex<\/span>","<span class=\"advgb-post-tax-term\">Idera Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Immune Design<\/span>","<span class=\"advgb-post-tax-term\">InDex Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">industry reports<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Mologen<\/span>","<span class=\"advgb-post-tax-term\">Novimmune<\/span>","<span class=\"advgb-post-tax-term\">pharma consultant<\/span>","<span class=\"advgb-post-tax-term\">pharma reports<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical reports<\/span>","<span class=\"advgb-post-tax-term\">TLR1-TLR10<\/span>","<span class=\"advgb-post-tax-term\">Toll Like Receptor ModulatorsAmpligen<\/span>","<span class=\"advgb-post-tax-term\">Toll-like receptors<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Dec 4, 2017","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Dec 4, 2017 11:40 am","modified":"Updated on May 12, 2025 2:41 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2443"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2443\/revisions"}],"predecessor-version":[{"id":32062,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2443\/revisions\/32062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2444"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2443"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2443"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}